Swiss Biotech – Industry news, events, directory, Swiss Biotech Association

May 4-5, 2026

The power of international collaboration

Get the insight

Swiss Biotech Report 2025

In print & digitally

The leading compedium of Swiss Biotech

How did we fare in 2024?

Our association in facts and figures

Become a Member

Loads of reasons to join

Invest in Swiss biotechs

Discover investment and partnering opportunities

Talent meets opportunities

Become part of the thriving community

Create lasting business ties

Connect with the Swiss biotech ecosystem

Get the insight

Swiss Biotech Report 2025

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Akceso Advisors AG, a leading independent global advisory firm specializing in market access, pricing, reimbursement strategy, operations and policy-setting for life-science companies and authorities, announced today the election of Dr. Seng Chin Mah as a new non-executive member of its Board of Directors.
February 10, 2026

abc biopply announces today the opening of its new Organoid Competence Center at the Swiss Innovation Park Basel. With this new location, the company expands its portfolio of highly standardized and fully integrated Organoid CRO services and brings them for the first time to Basel — one of the world’s leading hubs for drug discovery and development.
February 5, 2026

PSI CRO, a Swiss-based global full-service contract research organization (CRO), today announced the launch of SYNETIC, a next-generation AI-powered semantic knowledge platform that empowers sponsors to identify optimal trial sites, minimize startup delays, and predict and eliminate non-enrolling sites.
January 29, 2026

leadXpro AG (“leadXpro”), a Switzerland-based pharmaceutical research and development company, and Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, today announced that they have entered into a collaboration agreement focused on expanding the therapeutic potential and supporting the future out-licensing of LeadXpro’s adenosine A2B receptor (A2BR) antagonist
January 28, 2026